Read what the CSO of NuGenerex Immuno-Oncology, a
Post# of 36537
(Total Views: 335)
Posted On: 04/01/2020 12:37:57 PM
Read what the CSO of NuGenerex Immuno-Oncology, a #GNBT subsidiary, has to say about a #coronavirus #vaccine in the @PharmTechGroup article "Can Vaccine Development Be Safely Accelerated?": https://bit.ly/2xEEbkc
Pharmaceutical Technology provides professionals with dynamic and reliable cutting-edge peer-reviewed content and features on next-generation process development and manufacturing, formulation, drug delivery, ingredients, regulation, analytics, packaging, supply-chain, and outsourcing. Readers include senior executives, manufacturing managers, heads of procurement and those involved in research and development within major pharmaceutical firms.
Best,
Joseph Moscato
President & Chief Executive Officer
jmoscato@generex.com
Pharmaceutical Technology provides professionals with dynamic and reliable cutting-edge peer-reviewed content and features on next-generation process development and manufacturing, formulation, drug delivery, ingredients, regulation, analytics, packaging, supply-chain, and outsourcing. Readers include senior executives, manufacturing managers, heads of procurement and those involved in research and development within major pharmaceutical firms.
Best,
Joseph Moscato
President & Chief Executive Officer
jmoscato@generex.com
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼